FP&A Manager - Sales & Marketing and Revenue
Description :
Reporting to the Head of FP&A, you will be the primary finance business partner for the Company's US Sales & Marketing organization, working closely with a wide range of stakeholders across Sales, Marketing, and Market Access.
You will also oversee the Company's Gross-to-Net (GTN) revenue estimates and financial reporting. Most of the GTN modeling and data processing is outsourced to a specialized third-party provider (Integrichain / ICH); in this role, you will control, challenge, and validate the work performed by ICH rather than build or maintain the underlying models yourself.
Location : Warren, New Jersey - minimum 3 days on site
Salary Range : $140-160k
Key Responsibilities :
FP&A / Business Partnering – Sales & Marketing (Priority #1):
• Act as the lead finance business partner for US Sales & Marketing leadership, managing a wide range of stakeholders and moving parts across the organization.
• Lead the annual budgeting, quarterly forecasting, and long-range planning processes for Sales & Marketing expenses.
• Analyze trends and variances against budget/forecast, provide decision-support indicators, and identify risks and opportunities across all partnered functions.
• Support senior leaders (VP Sales, VP Marketing, and Market Access) on investments, projects, contracts, and resource allocation decisions.
• Challenge business owners on their forecasts and planning assumptions; ensure spend discipline and visibility across a broad and evolving set of partners.
• Actively participate in the monthly and quarterly financial closing process for the Sales & Marketing scope.
Revenue & Gross-to-Net (GTN) – Oversight & Control:
• Oversee and control the Gross-to-Net (GTN) estimates and deliverables prepared by the Company's outsourced GTN provider (Integrichain / ICH), rather than building or maintaining the GTN models directly.
• Review and challenge ICH's monthly and quarterly GTN accruals (rebates, chargebacks, discounts, returns, Medicaid/Medicare/340B, distribution and prompt-pay fees) for completeness and accuracy.
• Act as the main internal point of contact with ICH, ensuring deliverables are timely, well-documented, and aligned with contract terms and business assumptions.
• Monitor GTN ratios and deductions as a percentage of gross sales, flagging unexpected trends or variances to Accounting and senior Finance leadership.
• Ensure GTN estimates and revenue recognition are compliant with US GAAP (ASC 606) and support internal/external audit requests.
Contribution to Financial Reporting:
• Contribute to the preparation of US GAAP financial disclosures (10-Q, 10-K) related to revenue, GTN reserves, and Sales & Marketing expenses during quarterly and annual closings.
• Prepare management reporting packages and Board/Executive Committee materials on commercial and revenue performance.
Continuous Improvement:
• Contribute to the enhancement and automation of Sales & Marketing and GTN reporting and planning tools.
• Integrate non-financial KPIs into financial models and management reporting.
• Improve existing processes to strengthen the reliability, timeliness, and relevance of financial information.
Ensure internal control procedures (SOX) are properly implemented and maintained within the scope
Qualifications :
Bachelor's degree in Finance, Accounting, or Business Administration required; MBA, CPA, or CMA is a plus
Minimum 5–7 years of progressive FP&A or commercial finance experience, ideally within the biotech/pharmaceutical industry, including exposure to Sales & Marketing business partnering.
• A few years of experience as a manager (or senior analyst) within a Gross-to-Net (GTN) team is sufficient; deep GTN model-building expertise is not required, as most GTN activities are outsourced to a specialized third-party provider (Integrichain / ICH).
Experience managing or overseeing outsourced service providers / vendors is a plus.
• Advanced proficiency in Microsoft Excel and PowerPoint; experience with ERP/EPM systems (e.g., Dynamics, SAP, Oracle, Anaplan, Hyperion) required.
• Working knowledge of US GAAP revenue recognition (ASC 606) and the main components of Gross-to-Net (rebates, chargebacks, discounts, Medicaid/Medicare/340B), sufficient to control and challenge third-party deliverables.
• This is a high-exposure role requiring strong business partnering capabilities, with direct interaction with a broad and evolving set of stakeholders across Sales, Marketing, and Market Access functions.
• Rigor, autonomy, responsiveness, and the ability to operate in a demanding, fast-paced environment with many moving parts are essential.
Strong analytical skills, ability to prioritize, proactive mindset, synthesis skills, and intellectual curiosity are key to success in this role.
Behavioral skills :
Curiosity: Keep on exploring uncharted territories. Always ask “why?” and more importantly “why not?”,
Courage: Take smart risks, mentor each other to always do better & be accountable for our choices, our opinions, and our actions,
Collaboration: Teamwork and spirit. Support each other and be equally involved in the achievement of our common goals,
Credibility: Be transparent, follow through and build trust. Educate ourselves about our unique technology.
- Department
- Finance
- Location
- US - Warren, NJ
- Remote status
- Hybrid
- Employment type
- Full-time
About DBV Technologies
DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians who believed that food allergies could one day be treated safely and effectively.
We are on a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin™, to develop treatment options for immunologic diseases with significant unmet medical need.
This mission drives our commitment to the advancement of treatments for patients and their families. That is why we are investigating a potential new class of immunotherapy, epicutaneous immunotherapy (EPIT), that aims to re-educate the immune system of patients through the skin.
Today, we are focused on exploring the use of Viaskin to address food allergies, a devastating condition that afflicts millions of patients. As an important milestone in our journey, we hope to offer the first epicutaneous immunotherapy treatment for peanut allergy.
Tomorrow, as pioneers, we will continue to explore the broad applications of this potential new class of immunotherapy, including treatments for patients suffering from inflammatory and autoimmune diseases.